EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Combination of CD300c Antibody with PD-1 Blockade Suppresses Tumor Growth and Metastasis by Remodeling the Tumor Microenvironment in Triple-Negative Breast Cancer

Soyoung Kim iD, Ik-Hwan Han iD, Suin Lee, DaeHwan Park, Hyunju Lee, Jongyeob Kim iD, Joon Kim iD, Jae-Won Jeon, Hyunsu Bae iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26115045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Soyoung Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Science in Korean Medicine, College of Korean Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic o…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Tumor Microenvironment, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and ICT; Ministry of Trade, Industry and Energy; and Ministry of Health and Welfare, Republic of Korea, Korea Dementia Research Center funded by the Ministry of Science and ICT; Ministry of Health and Welfare; and Korea Health Industry Development Institute, Repu….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is an aggressive cancer characterized by a high risk of recurrence, invasiveness, metastatic potential, and poor prognosis. Tumor-associated macrophages (TAMs), particularly M2-like TAMs, contribute to TNBC progression by promoting an immunosuppressive tumor microenvironment (TME), highlighting the need for TME remodeling. This study aimed to evaluate the therapeutic efficacy of co-administering CL7, a CD300c monoclonal antibody that induces M1 macrophage polarization, and anti-PD-1, an immune checkpoint inhibitor, in TNBC. To establish a TNBC model, 4T1 cells were inoculated into the fourth left mammary gland of mice. CL7 and anti-PD-1 were intravenously administered twice a week. Flow cytometry and RT-PCR were performed to assess the immunotherapeutic effects, and lung metastases were evaluated by the Hematoxylin and Eosin staining of lung tissues. Tumor growth was significantly reduced in the combination treatment group (CL7 and anti-PD-1) compared to both the PBS and monotherapy groups. Additionally, the combination treatment increased M1 macrophages and activated CD8+ T and NK cells in the tumor, while significantly suppressing lung metastases. These findings suggest that the combination of CL7 and anti-PD- therapy has the potential to treat TNBC by remodeling the TME.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsTumor MicroenvironmentProgrammed Cell Death 1 ReceptorAntibodies, MonoclonalImmune Checkpoint InhibitorsAnimalsFemaleMiceCell Line, TumorHumansMice, Inbred BALB CTumor-Associated MacrophagesCD8-Positive T-LymphocytesLung NeoplasmsMacrophagesNeoplasm MetastasisCell Proliferation

Stichwörter der Autor:innen

CD300cCL7anti-PD-1breast cancercombination therapytumor associated macrophage

Substanzen

Programmed Cell Death 1 ReceptorAntibodies, MonoclonalImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Science in Korean Medicine, College of Korean Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.
  • CentricsBio Inc., 28 Beobwon-ro 11-gil, Songpa-gu, Seoul 05836, Republic of Korea.

ORCID-Profile: Soyoung Kim, Ik-Hwan Han, Jongyeob Kim, Joon Kim, Hyunsu Bae

Förderung

  • Ministry of Science and ICT; Ministry of Trade, Industry and Energy; and Ministry of Health and Welfare, Republic of Korea
  • Korea Dementia Research Center funded by the Ministry of Science and ICT; Ministry of Health and Welfare; and Korea Health Industry Development Institute, Repu…

Zitieren

APA

Kim, S., Han, I. H., Lee, S., Park, D., Lee, H., Kim, J., Kim, J., Jeon, J. W., & Bae, H. (2025). The Combination of CD300c Antibody with PD-1 Blockade Suppresses Tumor Growth and Metastasis by Remodeling the Tumor Microenvironment in Triple-Negative Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26115045

Vancouver

Kim S, Han IH, Lee S, Park D, Lee H, Kim J, et al. The Combination of CD300c Antibody with PD-1 Blockade Suppresses Tumor Growth and Metastasis by Remodeling the Tumor Microenvironment in Triple-Negative Breast Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26115045

BibTeX
@article{Kim2025,
  author = {Kim, Soyoung and Han, Ik-Hwan and Lee, Suin and Park, DaeHwan and Lee, Hyunju and Kim, Jongyeob and Kim, Joon and Jeon, Jae-Won and Bae, Hyunsu},
  title = {The Combination of CD300c Antibody with PD-1 Blockade Suppresses Tumor Growth and Metastasis by Remodeling the Tumor Microenvironment in Triple-Negative Breast Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26115045}
}
Kostenlos starten →